Cell-Based Immunotherapies

- 基於細胞的免疫療法 -

New for 2020, The Cell-Based Immunotherapy stream focuses on the latest protein engineering, clinical and analytical strategies driving the development of cell-based immunotherapies such as CAR Ts, TCRs, TILs and NKs, for the treatment of cancer and immune disorders. Topics include improving target identification, optimizing product design, specificity, safety, characterization and analytics.

Conferences Include:

5月4 - 5日

Improving Immunotherapy Efficacy and Safety
( 提升免疫療法有效性和安全性 )

5月6 - 7日

CAR Ts, TCRs and TILs

5月7 - 8日

Cell and Gene Therapy Analytics
( 細胞療法和基因療法分析 )

Keynote Speakers:


Prasad Adusumilli, MD, FACS, FCCP Deputy Chief and Associate Attending, Thoracic Surgery; Director, Mesothelioma

Adrian Bot, PhD Vice President, Translational Medicine, Kite Pharma, a Gilead Company

Jan Joseph (Jos) Melenhorst, PhD Adjunct Associate Professor, Pathology & Laboratory Medicine, University of Pennsylvania

Jeffrey Miller, MD Professor of Medicine, Deputy Director, Masonic Cancer Center, Division of Hematology, Oncology and Transplantation, University of Minnesota

Choose your language